These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
3 files

Dethioacylation by Sirtuins 1–3: Considerations for Drug Design using Mechanism-based Sirtuin Inhibition

revised on 01.02.2020, 10:54 and posted on 03.02.2020, 12:28 by Nima Rajabi, Alexander Lund Nielsen, Christian Adam Olsen
The sirtuin enzymes are potential drug targets for intervention in a series of diseases. Efforts to inhibit enzymes of this class with thioamide- and thiourea-containing, substrate-mimicking entities have produced a number of high-affinity binders. However, less attention has been dedicated to the investigation of the stability of these inhibitors under various conditions. Here, we provide evidence of unprecedented degree of cleavage of short-chain epsilon-N-thioacyllysine modifications meant to target these sirtuins and further provide insights into the serum stability of compounds containing both thioamides and thioureas. Our study questions the utility short-chain thioamide-based inhibitors of sirtuins for drug development and points to application of mono-alkylated thiourea-based chemotypes as more promising for targeting sirtuins 1 and 3, in particular.


Lundbeck Foundation (Running Cost grant R289-2018-2074)

Carlsberg Foundation (CF15-0115)

Novo Nordisk Foundation (NF15OC0017334)

European Research Council (ERC-CoG-725172–SIRFUNCT)


Email Address of Submitting Author


University of Copenhagen



ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest